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Background: Insulin aspart (IAsp) and its biphasic preparations BIAsp50 and BIAsp70 (containing 50% and 70%
IAsp, respectively) have distinct glucose-lowering properties as compared to human insulin (HI). We investigated
whether this affected the circulating IGF-system which depends on the hepatic insulin exposure.
Methods: In a randomized, four-period crossover study, 19 patients with type 1 diabetes received identical doses
(0.2 U/kg sc) of IAsp, BIAsp70, BIAsp50 and HI together with a standardized meal. Serum total IGF-I and IGFBP-1
to −3 were measured by immunoassays for nine hours post-prandially. Bioactive IGF was determined by an in-house,
cell-based IGF-I receptor kinase activation (KIRA) assay.
Results: Despite marked differences in peripheral insulin concentrations and plasma glucose, the four insulin preparations
resulted in parallel decreases in IGFBP-1 levels during the first 3 hours, and parallel increases during the last part of the
study (3–9 hours). Thus, only minor significances were seen. Insulin aspart and human insulin resulted in a lower area
under the curve (AUC) during the first 3 hours as compared to BIAsp70 (p = 0.009), and overall, human insulin resulted in
a lower IGFBP-1 AUC than BIAsp70 (p = 0.025). Nevertheless, responses and AUCs of bioactive IGF were similar for all four
insulin preparations. Changes in levels of bioactive IGF were inversely correlated to those of IGFBP-1, increasing during the
first 3 hours, whereafter levels declined (−0.83≤ r≤−0.30; all p-values <0.05).
Total IGF-I and IGFBP-3 remained stable during the 9 hours, whereas IGFBP-2 changed opposite of IGFBP-1, increasing
after 3–4 hours whereafter levels gradually declined. The four insulin preparations resulted in similar profiles and AUCs
of total IGF-I, IGFBP-2 and IGFBP-3.
Conclusions: Despite distinct glucose-lowering properties, the tested insulin preparations had similar effects on IGF-I
concentration and IGF bioactivity, IGFBP-2 and IGFBP-3 as compared to HI; only small differences in IGFBP-1 were
seen and they did not affect bioactive IGF. Thus, insulin aspart containing preparation behaves as HI in regards to the
circulating IGF-system. However, bioactive IGF appeared to be more sensitive to insulin exposure than total IGF-I. The
physiological significance of this finding remains to be determined.
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In patients with type 1 diabetes (T1D), insulinopenia in the
portal circulation leads to alterations of the growth hor-
mone - insulin-like growth factor I - insulin-like growth
factor binding protein (GH - IGF-I - IGFBP) axis [1], in-
cluding GH hypersecretion, reduced circulating levels of
IGF-I and IGFBP-3, and elevated levels of IGFBP-1 and −2
[2-4]. Due to the insulin antagonizing effects of GH and
the insulin sensitizing effects of IGF-I, these alterations
are likely to have a negative effect on whole body
insulin resistance [5,6] and they may also contribute to the
development of long-term complications. Thus, in T1D
one hypothesis has linked the augmented secretion of GH
with the development of diabetic retinopathy [7] and
nephropathy [8]. Supportive of this, intensified subcutane-
ous insulin therapy can improve metabolic control,
return changes in the GH-IGF-axis towards normal and
decrease progression of diabetes complications in patients
with T1D [9]. However, it is worth to realize that not
even excellent glycemic control can fully normalize the
GH-IGF-I-IGFBP axis [2].
Insulin aspart, a rapid-acting insulin analogue, has been
employed in intensified insulin therapy for many years.
After subcutaneous injection, insulin aspart is absorbed
faster and eliminated more quickly than human insulin,
thus it has a more physiological insulin profile [10]. The
pharmacokinetic profile of insulin aspart can be extended
by combining soluble insulin aspart with protamine insu-
lin aspart, but even this formulation has a faster onset of
action than human insulin. Thus, a previous clinical study
demonstrated that insulin aspart as well as mixtures of
soluble and protamine insulin aspart (i.e. BIAsp70 and
BIAsp50 which contains 70% and 50% rapid-acting insulin
aspart and 30% and 50% protamine insulin aspart, respect-
ively), are absorbed twice as fast as human insulin and as-
sociate with higher peak concentrations [11]. Based on
these observations we hypothesized that the distinct per-
ipheral insulin profiles obtained with the abovementioned
insulin preparations could translate into distinct hepatic
exposures to insulin and in this way affect the liver pro-
duction of IGF-I and IGFBPs differently. However, this
assumption has not been tested under controlled and
standardized circumstances.
The aim of the present trial was to compare the serum
profiles of IGF-I and the IGFBPs after a subcutaneous
injection with equal doses of insulin aspart, BIAsp70,
BIAsp50 or human insulin. In particularly, their effects
on the insulin-regulated IGFBP-1 had our interest, as
differences in IGFBP-1 may lead to secondary changes
in bioactive IGF.
Methods
This open-label, randomized, four-period crossover study
was approved by the central Denmark region committeeson health research ethics and the Danish Medical Agency.
The study was carried out according to the Declaration of
Helsinki and the principles of Good Clinical Practice.
Written informed consent was obtained from all the
participants before any study related activities. Findings
related to the pharmacokinetic and pharmacodynamic
profiles of human insulin vs. the three different insulin
aspart preparations have recently been published else-
where [11].
Patients
Patients of both genders with T1D, aged ≥ 18 years, with
HbA1c of 53–108 mmol/mol (7-12%) and body mass
index (BMI) of 18–35 kg/m2 were recruited. Patients
had to have the clinical diagnosis of diabetes before the
age of 40 years and to be treated with any insulin regi-
men for ≥ 12 months at a daily insulin dose ≥ 0.4 U/kg.
Exclusion criteria included patients who had allergy to
investigational insulin, recurrent major hypoglycemia
(defined as >2 severe hypoglycemic episodes within the
last 12 months), acute myocardial infarct < 12 months or
severe heart insufficiency, abnormal liver and kidney
function (estimated by routine laboratory biochemical
testing), pregnancy or breast-feeding. Some patients re-
ceived other prescribed drugs than insulin; however, this
medication remained unaltered during the entire study.
Procedures
The study comprised four study visits (at least one week
apart), where insulin aspart, BIAsp70, BIAsp50 or human
insulin were administrated in random order. By choosing
a crossover design where each patient served as his or her
own control, we aimed to reduce the influence of inter-
individual differences in regards to for instance insulin
sensitivity. Patients reported to the clinical research unit
at 9:00 p.m. on the night prior to the profile day. They
were thoroughly instructed to inject the last dose of basal
insulin at least 24 hours before administration of the study
insulin. During the overnight fast, intravenous infusions of
isotonic glucose and insulin were administered to main-
tain blood glucose values between 5 and 8 mM and by
this, to attain a comparable baseline glucose level prior to
study insulin injection. Infusions were commenced at
10:00 p.m. and ended at 8:00 a.m. Soluble human insulin
(Actrapid®, Novo Nordisk) was infused during the night
prior to the morning injection of insulin aspart prepara-
tions. Conversely, insulin aspart was infused before the
morning injection of human insulin. Blood glucose was
measured every 30 min over night. Before the insulin in-
jection, the glucose values had to be within the defined
range for at least 30 min. In the morning of the profile
day, a single dose (0.2 U/kg) of either insulin aspart,
BIAsp70, BIAsp50 or human insulin (Actrapid®, Novo
Nordisk) was injected subcutaneously at the abdomen.
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before the meal, which started at 8 a.m., whereas human
insulin was injected 30 min before the meal. The stan-
dardized meal contained 3360 kJ fat, carbohydrate and
protein and was finished within 15 min. From 8:00 a.m.
(baseline), blood samples were drawn hourly for deter-
mination of serum concentrations of IGFBP-1 and
IGFBP-2, while total IGF-I, bioactive IGF and IGFBP-3
were measured at 0, 3, 6, and 9 hours.
Blood glucose was measured every hour with the
plasma glucose meter (Ascensia Contour, Bayer) for
safety assessment and more often if needed. Patients
were treated with oral glucose (equal to 40 g glucose)
or intravenous injection of 10% glucose if the blood
glucose measurement was below 3.1 mM. Study proce-
dures were discontinued when the patient’s glucose
measurement exceeded 16.0 mM.Laboratory assessment
All the variables were analyzed in serum. Samples were
stored at −80°C until analysis.
Total IGF-I and IGFBP-3 levels were determined by
commercial chemiluminescence immunoassays on the
IDS-iSYS multi-discipline automated analyzer (Immu-
nodiagnostic Systems Nordic SA, Denmark) according
to the manufacturer’s protocol, as recently published
[12,13]. Limits of detection for total IGF-I and IGFBP-3
were 4.4 μg/l and 50 μg/l respectively.
IGFBP-1 was determined by an in-house time-resolved
immunofluorometric assay (TR-IFMA) with slight modifi-
cations as recently described [14]. IGFBP-2 was determined
by a validated in-house time-resolved immunofluorometric
assay (TR-IFMA) as previously described [15]. The IGFBP-1
and −2 assays have intra- and inter-assay CVs aver-
aging <5% and <12%.
Bioactive IGF was determined by an IGF-I kinase recep-
tor activation (KIRA) assay based on human IGF-I recep-
tor gene-transfected embryonic renal cell as described by
Chen et al. [16] with slight modifications [14]. In brief,
transfected cells were stimulated for 15 min at 37°C with
either IGF-I standards (WHO 02/254) or diluted serum.
After cells were aspirated and the cells lysed, the crude
cell lysates were transferred to a TR-IFMA assay to detect
the concentration of phosphorylated IGF-I receptors. The
KIRA assay also detects IGF-II and pro-IGF-II activation
of the IGF-IR with a cross-reactivity of 12% and 2%, re-
spectively. Although the majority of the KIRA assay sig-
nal obtained in serum without any doubt originates
from an IGF-I induced activation of the IGF-IR, IGF-II
is likely to participate and accordingly, the output of the
KIRA assay has been named “IGF bioactivity”. By con-
trast, the cross reactivity of proinsulin, insulin and insu-
lin analogues were less than 1%. The KIRA assay has adetection limit < 0.1 μg/l, and intra- and inter-assay CVs
of <7% and <15%, respectively.
Statistical analysis
A power analysis showed that 19 completed subjects
would be required to yield a statistical power of 90% to
detect an absolute difference of 10 μg/l between the mini-
mum concentrations of IGFBP-1. Thus, to allow dropouts
we invited 24 subjects to participate. Statistical analyses
were performed using IBM SPSS Statistics version 20.0
(IBM Corp., Somers, NY, USA). Komogorov-Smirnov test
was used to test for normal distribution. Natural logarith-
mic transformation was performed to improve the distri-
bution of raw data. Area under the concentration-time
curve (AUC) was calculated by the trapezoidal rule for the
time intervals 0–3 hours (AUC0–3), 3–6 hours (AUC3–6),
6–9 hours (AUC6–9) and for all 9 hours (AUC0–9). The
differences in Cmax, Cmin, tmax, tmin and AUCs were
determined using analysis of variance (ANOVA) with
treatment as a fixed factor and patient as a random factor.
The baselines levels were used as co-variables in the
ANOVA analyses for the AUC0–3 and AUC0–9. If a pa-
tient discontinued earlier than planned, ANOVA tests
were only performed for his/her completed periods. If
the ANOVA was significant, the difference between
treatments was examined statistically by using the Bon-
ferroni method. Analysis of time-related effects among
groups was performed using repeated measures ANOVA.
Linear correlations were used to assess relationships be-
tween measured variables. P values <0.05 were considered
statistically significant.
Results
Nineteen patients (15 men and 4 women), aged 40.7
(22–63) years (mean and range), with a BMI of 25.5
(20.6-30.3) kg/m2, a duration of T1D of 20.9 (3–47)
years and a present HbA1c of 66 (53–84) mmol/mol
[8.2 (7.0-9.8)%] underwent all four study visits. The profile
day was ended after six hours of insulin injection for three
patients with the insulin aspart treatment and for one pa-
tient with human insulin, because their glucose levels
exceeded 16.0 mM as defined by study protocol. The rest
of the patients completed the nine hours experimental
period of all four study visits.
Insulin and glucose
Figure 1a and b illustrate the insulin and glucose profiles
during nine hours period, as recently published [11]. In
brief, results showed that the insulin and glucose profiles
following sc injection of human insulin differed signifi-
cantly from those of the insulin aspart preparations.
BIAsp50 demonstrated the greatest similarity to human
insulin as regards pharmacokinetic and pharmacody-
namic profiles [11].
Figure 1 Insulin and glucose profiles. Serum insulin concentration (a) and plasma glucose concentration (b) during 9-hour treatment with
insulin aspart (open circles), BIAsp70 (black rectangles), BIAsp50 (open rectangles) and human insulin (black circles). The arrow indicates human
insulin injection time, and the vertical dotted line indicates the time of meal. Serum insulin and plasma glucose profiles are illustrated as mean
levels (reprinted with permission from Diabetes Technology & Therapeutics).
Ma et al. BMC Endocrine Disorders 2014, 14:35 Page 4 of 11
http://www.biomedcentral.com/1472-6823/14/35Baseline IGF levels
At baseline, serum concentrations of total IGF-I, bioactive
IGF and IGFBP-1 to −3 were comparable among the four
treatment days (Table 1).
Changes in IGF levels during the nine hours of study
None of the investigational insulin preparations changed
serum total IGF-I levels from baseline (Figure 2a). Simi-
larly, maximum and minimum concentrations of totalIGF-I were similar for insulin aspart preparations and
human insulin. There were no significant differences in
the AUCs of total IGF-I in any time interval during the
study (Table 1).
For all four insulin preparations, serum IGF bioactivity
increased during the first three hours. As compared to
baseline levels, these increases were significant following
insulin aspart (+18%) and human insulin (+28%), and insig-
nificant for BIAsp70 (+9%) and BIAsp50 (+12%) (Figures 2b
Table 1 Results of IGF parameters
Parameter Unit Insulin aspart (a) BIAsp70 (b) BIAsp50 (c) Human insulin (d) p
Total IGF-I
Baseline μg/l 113 (109–117) 121 (116–125) 117 (113–121) 115 (111–120) NS
Cmax μg/l 124 (121–126) 124 (122–126) 122 (120–125) 122 (119–124) NS
Cmin μg/l 113 (111–114) 113 (111–115) 112 (110–114) 113 (111–115) NS
AUC0-3 h μg*h/l 353 (349–357) 355 (351–359) 353 (349–357) 353 (350–357) NS
AUC3-6 h μg*h/l 349 (337–362) 370 (358–383) 356 (344–369) 352 (340–365) NS
AUC6-9 h μg*h/l 346 (333–361) 364 (352–378) 351 (339–364) 349 (336–362) NS
AUC0-9 h μg*h/l 1071 (1053–1090) 1071 (1055–1088) 1059 (1043–1074) 1064 (1048–1081) NS
Bioactive IGF
Baseline μg/l 0.60 (0.54-0.67) 0.62 (0.56-0.69) 0.68 (0.61-0.76) 0.58 (0.52-0.65) NS
Cmax μg/l 0.80 (0.76-0.84) 0.79 (0.75-0.83) 0.79 (0.75-0.84) 0.82 (0.78-0.87) NS
Cmin μg/l 0.46 (0.43-0.50) 0.50 (0.47-0.54) 0.52 (0.49-0.56) 0.52 (0.48-0.56) NS
AUC0-3 h μg*h/l 2.02 (1.96-2.09) 1.96 (1.90-2.02) 2.04 (1.98-2.11) 2.08 (2.02-2.15) .051
AUC3-6 h μg*h/l 2.16 (2.02-2.31) 2.11 (1.98-2.25) 2.26 (2.11-2.41) 2.27 (2.13-2.43) NS
AUC6-9 h μg*h/l 1.82 (1.68-1.98) 1.90 (1.76-2.05) 1.99 (1.85-2.15) 1.98 (1.83-2.14) NS
AUC0-9 h μg*h/l 6.11 (5.80-6.45) 5.98 (5.71-6.27) 6.18 (5.89-6.49) 6.43 (6.12-6.75) NS
IGFBP-1
Baseline μg/l 130 (107–159) 140 (115–171) 116 (95–141) 144 (118–176) NS
Cmin μg/l 14 (11–18)c 21 (16–27) 26 (20–34)a 22 (17–29) .009
Tmin min 259 (234–284) 256 (231–280) 231 (206–255) 268 (244–293) NS
AUC0-3 h μg*h/l 262 (233–294)c 319 (284–359) 351 (312–396)a,d 256 (228–288)c .001
AUC3-6 h μg*h/l 112 (81–155) 132 (96–183) 164 (119–227)d 83 (60–114)c .029
AUC6-9 h μg*h/l 662 (496–884) 577 (445–747) 455 (351–589) 390 (298–510) NS
AUC0-9 h μg*h/l 1092 (906–1317) 1084 (917–1282)d 1032 (871–1224) 779 (654–927)b .025
IGFBP-2
Baseline μg/l 342 (312–375) 356 (324–390) 356 (325–391) 380 (347–417) NS
Cmax 0-6 h μg/l 477 (459–497) 473 (455–493) 462 (444–480) 465 (447–485) NS
Tmax 0-6 h min 215 (185–245) 215 (185–245) 218 (188–248) 205 (175–235) NS
AUC0-3 h μg*h/l 1225 (1191–1261) 1224 (1189–1259) 1184 (1151–1219) 1212 (1177–1247) NS
AUC3-6 h μg*h/l 1278 (1170–1395) 1303 (1194–1423) 1263 (1157–1378) 1363 (1249–1488) NS
AUC6-9 h μg*h/l 1127 (1015–1251) 1261 (1149–1385) 1221 (1112–1340) 1247 (1132–1374) NS
AUC0-9 h μg*h/l 3717 (3548–3892) 3758 (3609–3916) 3640 (3495–3792) 3651 (3498–3813) NS
IGFBP-3
Baseline mg/l 3.04 (2.97-3.11) 3.12 (3.05-3.19) 3.05 (2.97-3.12) 3.01 (2.94-3.08) NS
Cmax mg/l 3.30 (3.23-3.37) 3.32 (3.25-3.39) 3.30 (3.24-3.37) 3.25 (3.18-3.32) NS
Cmin mg/l 2.98 (2.94-3.02) 3.00 (2.96-3.04) 2.98 (2.94-3.02) 2.99 (2.95-3.03) NS
AUC0-3 h mg*h/l 9.23 (9.12-9.34) 9.22 (9.11-9.33) 9.23 (9.12-9.34) 9.20 (9.09-9.31) NS
AUC3-6 h mg*h/l 9.40 (9.16-9.66) 9.67 (9.42-9.93) 9.44 (9.19-9.69) 9.26 (9.02-9.51) NS
AUC6-9 h mg*h/l 9.45 (9.19-9.72) 9.87 (9.63-10.12) 9.60 (9.36-9.84) 9.46 (9.22-9.71) NS
AUC0-9 h mg*h/l 28.19 (27.71-28.68) 28.50 (28.05-28.94) 28.33 (27.90-28.77) 28.16 (27.71-28.61) NS
The results for Cmax, Cmin, Tmax, Tmin and AUCs are expressed as geometric mean (range) drawn from ANOVA. The outcomes were controlled for baseline levels
(t = 0) if necessary, ap < 0.05 vs insulin aspart, bp < 0.05 vs BIAsp70, cp < 0.05 vs BIAsp50, dp < 0.05 vs human insulin.
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Figure 2 IGF parameters profiles. (a) Serum total IGF-I concentration, (b) bioactive IGF concentration, (c) IGFBP-1 concentration, *P < 0.01 as
BIAsp50 compared with insulin aspart and human insulin for AUC0–3; **P < 0.05, as BIAsp50 compared with human insulin for AUC3–6; ***P < 0.05,
as BIAsp70 compared with human insulin for AUC0–9. (d) IGFBP-2 levels and (e) IGFBP-3 levels during 9-hour treatment with insulin aspart (open
circles), BIAsp70 (black rectangles), BIAsp50 (open rectangles) and human insulin (black circles). For clarity, serum concentrations are illustrated as
mean levels only.
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cantly (all p-values <0.05) during the last three hours, irre-
spective of study insulin (Figures 2b and 3a). In regards to
Cmax, Cmin and the AUCs, no statistical significantdifferences in bioactive IGF were found between the four
insulin preparations (Table 1).
For all four insulin preparations, linear regression ana-
lysis showed that changes in IGFBP-1 correlated inversely
Figure 3 Changes in IGF bioactivity and IGFBP-1. IGF bioactivity (a) and IGFBP-1(b) levels during 0–3 hours and 6–9 hours. Asterisks indicate
that significant change was found in comparison with previous level (p < 0.05).
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Three hours after the administration of study insulin,
serum IGFBP-1 reached nadir, whereafter levels
gradually increased to peak values at the end of the
study (all p-values <0.05). Although the four different
insulin preparations resulted in parallel changes in serum
IGFBP-1, a detailed analysis revealed minor but significant
differences when comparing the AUCs (for details please
refer to Table 1). In general, insulin aspart preparations
with higher proportions of the rapid-acting aspart inducedlower IGFBP-1 AUCs during the first six hours and higher
AUCs during the last three hours (Table 1).
Serum IGFBP-2 increased in the early phase of the pro-
file day whereafter levels declined towards baseline values.
Neither peak levels nor AUCs differed when comparing
the different insulin preparations (Table 1).
Serum IGFBP-3 remained unchanged during all four
profile days. Although IGFBP-3 appeared to display dif-
ferences during the last three hours, these differences
were insignificant (Figure 2e and Table 1).
Figure 4 Linear regression between the changes of IGF bioactivity and IGFBP-1 level. 0–3 hours (a) and 6–9 hours (b). The symbols
represent patients with insulin aspart (black circles), BIAsp70 (open circles), BIAsp 50 (black triangles) and human insulin (open triangles). For all
four insulin preparations a significant inverse correlation with IGFBP-1 was observed, being r = − 0.30 for insulin aspart, r = − 0.47 for BIAsp70,
r = − 0.40 for BIAsp50, and r = − 0.52 for human insulin group during 0–3 hours (a), while r = − 0.83 for insulin aspart, r = − 0.57 for BIAsp70,
r = − 0.40 for BIAsp50, and r = − 0.58 for human insulin group during 6–9 hours (b); all p-values <0.05. For clarity the reference line illustrates the
trend of data in four insulin groups.
Ma et al. BMC Endocrine Disorders 2014, 14:35 Page 8 of 11
http://www.biomedcentral.com/1472-6823/14/35Discussion
We have previously demonstrated that equal doses of hu-
man insulin, insulin aspart and the two biphasic aspart
preparations BIAsp50 and BIAsp70 have distinct pharma-
cokinetic and -dynamic properties in patients with T1D
[11] and this finding prompted us to investigate their
effect on the circulating IGF system, which is known to
respond to insulin. However, as scrutinized by the
present study, the distinct pharmacokinetic propertiesof the tested insulin preparations only affected IGFBP-1
and these changes were minor and hardly of any major
physiological significance. Supportive of this interpret-
ation, levels of bioactive IGF responded similarly to the
four insulin preparation and the same was true for total
IGF-I, IGFBP-2 and IGFBP-3. On the other hand, our
study clearly demonstrates bioactive IGF to be more
sensitive to short-term changes in insulin exposure than
total IGF-I. This observation highlights the important
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on the IGF system.
IGFBP-1 is the only component of the IGF system that
is directly regulated by insulin, which inhibits the hepatic
synthesis of IGFBP-1 at the transcriptional level [17-19].
As the liver is considered to be the main source of IGFBP-
1, its serum levels can be used to estimate the hepatic
exposure to insulin [17] as well as the hepatic sensitivity
to insulin [20]. As expected, serum IGFBP-1 declined after
sc administration of insulin, irrespective of type of insulin.
However, some differences were indeed observed when
comparing the four preparations. Overall, during the
9 hours of study human insulin resulted in the lowest
IGFBP-1 concentrations. Furthermore, pure aspart dif-
fered from the two biphasic aspart preparations when
comparing early and late effects, but overall the three
aspart-containing preparations yielded similar AUCs.
Whether these minor differences have any physiological
importance remain uncertain. However, IGFBP-1 is an
important regulator of free IGF-I [21] as well as bioactive
IGF [22], at least when measured in vitro, and as we
observed no differences in the response of bioactive IGF
to the four insulin preparations, we speculate that the
observed statistical differences in IGFBP-1 has little, if any
biological significance. Thus, we conclude that despite
clearly distinct pharmacokinetic and -dynamic profiles of
the four insulin preparations, this did not translate into
clearly distinct IGFBP-1 profiles. As we have no reasons to
believe that the insulin sensitivity of the participants chan-
ged during the study period, this indicates that the four
tested insulin preparations resulted in comparable hepatic
insulin exposures and this we believe is valuable clinical
information. Importantly, our observation is in agreement
with a previous publication by Hedman et al., who com-
pared 6 weeks of constant subcutaneous infusion of insu-
lin lispro vs. human insulin [23]. These authors observed
marked postprandial differences in blood glucose and
plasma insulin, whereas the postprandial excursions of
serum IGFBP-1 did not differ between the two insulin
preparations. Thus, it seems fair to conclude that the
glycemic response to rapid-acting insulin preparations
cannot be used to predict the response of the IGF-system.
Circulating IGFBP-1 only constitute a minor fraction
of the six IGFBPs [18] but it is, nevertheless, believed to
act as an important short-term regulator of IGF actions
in vivo [24]. Thus, it is generally believed that reductions
in circulating IGFBP-1 result in a diminution of IGF
binding capacity and consequently increases free and
subsequently bioactive IGF [5,24]. With the cell based
IGF-IR bioassay at hand we are able to determine the
ability of serum to activate the IGF-IR in vitro [16]. Our
findings demonstrated a strong interaction between IGF
bioactivity and circulating IGFBP-1 levels. During the
first three hours, a reduction in IGFBP-1 levels wasaccompanied by an increase in IGF bioactivity. Con-
versely, at the end of the profile day (6–9 h), the marked
increases in IGFBP-1 associated with a large decline in
IGF bioactivity. These findings illustrate the intimate
relationship between insulin and the IGF system and
suggests that in patients with T1D the actions of the IGF
system may be more fluctuating and dependent on insu-
lin administration than what is suggested from measure-
ments of total IGF-I. However, we acknowledge that the
clinical relevance of our finding needs to be clarified.
Unlike IGFBP-1 and bioactive IGF, total IGF-I and
IGFBP-3 remained constant during the nine hours of
study and no significant differences in total IGF-I out-
comes could be detected among the four insulin prepa-
rations. This finding was, however, not surprising as the
majority of circulating IGF-I is bound in ternary com-
plexes composed of IGFBP-3 and the acid-labile subunit
(ALS). These complexes are primarily dependent on GH
rather than insulin and furthermore characterized by a
circulating half-life of 12–15 hours [25,26].
Studies in humans and in experimental animal models
have shown that IGFBP-2 is a key factor in the insulin-
IGF cross-talk and also linked to insulin resistance
[27-30]. Our study demonstrated for the first time that
serum IGFBP-2 fluctuates after a meal-time insulin
injection in patients with T1D, hereby supporting its
metabolic relationship. As for IGFBP-1, the four insulin
preparations resulted in virtually similar changes in
IGFBP-2 levels, regardless of glycemic control. Whether
the increase in IGFBP-2 serves to counteract the impact
of IGFBP-1 on bioactive IGF remains unknown, but this
is most likely, as IGFBP-2 has been demonstrated to
correlate inversely with levels of bioactive IGF following
a hyperinsulinemic clamp [28].
The present study has some limitations that should be
taken into consideration for the interpretation of the re-
sults. Firstly, we compared peripheral levels of the differ-
ent insulin preparations and they could differ from levels
within the portal vein system. Secondly, we had a priori
decided to withdraw patients when their plasma glucose
exceeded 16 mM. This decision reduced the number of
samples collected at six and nine hours and it may have
contributed to underestimate any late occurring differ-
ences between the four insulin preparations. Thirdly, we
have to acknowledge that the calculated dose of insulin
was insufficient to maintain postprandial blood glucose
levels within normal range. Thus, we cannot fully pre-
clude that the use of higher insulin doses may have
enhanced our ability to detect significant differences in
the response of the IGF-system.
Molecular modification of human insulin, resulting in
insulin analogues, aims to improve pharmacokinetic
and -dynamic properties, but at the same time this may
increase IGF-IR binding affinity, hereby raising clinical
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strated that insulin aspart resembles human insulin in its
IGF-IR binding affinity and mitogenic potency [31]. In
fact, the capacity of insulin aspart to cross-react with the
IGF-IR in vitro was slightly lower than that of human
insulin [16]. These findings were supported by the present
clinical study demonstrating no increased IGF-IR activa-
tion in vitro following treatment with insulin aspart con-
taining preparations. Furthermore, all three insulin aspart
preparations had close to identical effects on the circulating
IGF system as compared to human insulin, the only excep-
tion being slight differences in IGFBP-1, which however,
were expected and in accordance with the pharmacokinetic
properties of the tested insulins. Thus, in regards to short
term effects on the circulating IGF system, our data yield
no reason to concern when using insulin aspart containing
preparations.Conclusion
The present study demonstrated that despite distinct
pharmacokinetic and -dynamic properties, insulin aspart
preparations had similar effects on IGF-I concentration
and IGF bioactivity as well as on levels of IGFBP-2 and
IGFBP-3 as compared to those of human insulin. Dif-
ferences were observed in regards to the very insulin
sensitive protein IGFBP-1, but the magnitude of these
differences were small and hardly on any major bio-
logical significance as they did not impact bioactive
IGF. On the other hand, bioactive IGF appeared to be
more sensitive to insulin exposure than total IGF-I, and
hence our study suggests that the activity of the IGF
system may be relatively dynamic in patients with T1D,
being dependent on the prevailing insulin levels. How-
ever, the clinical and pathophysiological importance of
such insulin-related fluctuations in IGF bioactivity re-
mains to be clarified.Abbreviations
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